Takeda Korea Pharmaceutical and the Korea Rare and Intractable Disease Association successfully held 'Angel Spoon Day' on February 26 to support families affected by rare and intractable diseases.
On March 6, Takeda Korea Pharmaceutical, led by CEO Park Kwang-kyu, and the Korea Rare and Intractable Disease Association, led by President Yoo Ji-hyun, announced the successful completion of 'Angel Spoon Day' on February 26, coinciding with Rare Disease Day, which is observed on the last day of February each year. The event, now in its fourth year, aims to restore psychological stability and vitality for families impacted by rare and intractable diseases. It was organized with a focus on supporting caregivers who often struggle to find time for themselves due to the responsibilities of caring for patients. The program included experiences that foster both physical and emotional renewal and encourage the determination to overcome health challenges.
The event featured a cultural experience program held in Yangsuri, Gyeonggi Province, involving 22 children with juvenile idiopathic arthritis and their siblings, along with 19 guardians and 17 employees from Takeda Korea Pharmaceutical. This initiative was designed to reconnect patients and their families, who often feel emotionally isolated during treatment. Participants enjoyed activities such as strawberry picking and jam making, providing them with new shared experiences, while caregivers had the opportunity to take a break from their daily caregiving roles and share their stories with one another.
Juvenile idiopathic arthritis, defined as arthritis lasting for at least six weeks in children under 15, starts with inflammation of the synovial membrane around the joints rather than the cartilage or bones. Continued inflammation can damage cartilage and bone, leading to joint deformities and reduced function. Managing this condition requires appropriate and ongoing treatment, including medication, physical therapy, and, in some cases, surgical intervention. Continuous treatment and management can help patients maintain their daily lives. Peter Trang, the head of management planning and DD&T at Takeda Korea, emphasized the significance of emotional stability and social connection in the management of rare diseases, stating that they are as crucial as medical treatment.
